KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Receivables - Other (2017 - 2025)

Historic Receivables - Other for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $24.2 million.

  • Amneal Pharmaceuticals' Receivables - Other rose 20808.4% to $24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year increase of 20808.4%. This contributed to the annual value of $9.1 million for FY2024, which is 792.63% down from last year.
  • According to the latest figures from Q3 2025, Amneal Pharmaceuticals' Receivables - Other is $24.2 million, which was up 20808.4% from $16.3 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Receivables - Other ranged from a high of $73.0 million in Q3 2022 and a low of $30000.0 during Q1 2023
  • Moreover, its 5-year median value for Receivables - Other was $14.5 million (2023), whereas its average is $19.2 million.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Receivables - Other crashed by 9993.65% in 2023, and later soared by 4257333.33% in 2024.
  • Over the past 5 years, Amneal Pharmaceuticals' Receivables - Other (Quarter) stood at $9.8 million in 2021, then surged by 239.13% to $33.1 million in 2022, then plummeted by 70.03% to $9.9 million in 2023, then decreased by 7.93% to $9.1 million in 2024, then soared by 164.71% to $24.2 million in 2025.
  • Its Receivables - Other was $24.2 million in Q3 2025, compared to $16.3 million in Q2 2025 and $20.5 million in Q1 2025.